Although the world is almost polio-free, vaccination remains necessary to prevent future outbreaks. Therefore, on assignment by the World Health Organization, Intravacc developed a new and promising Sabin-IPV polio vaccine. We used our proven platform technologies to swiftly develop an affordable and safe production technology. In recent clinical studies, Sabin-IPV was shown to be safe and immunogenic in adults and infants. Currently, this production technology and related quality controls are actively being transferred by hands-on training to local vaccine manufacturers in emerging economies. As a result, manufacturers in for example China, South Korea and India are enabled to safely produce the Sabin-IPV vaccine to vaccinate their local population.